Research Article

GEMIN6 Overexpression Correlates with the Low Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma

Yunsong Peng,1 Zeng Wang,1 Jianyong Cai,2 Xiaoqiao Dong3, and Quan Du3

1Department of Pharmacy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022 Zhejiang, China
2Department of Neurosurgery, The Wenzhou Central Hospital, Wenzhou, 325000 Zhejiang, China
3Department of Neurosurgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 Zhejiang, China

Correspondence should be addressed to Xiaoqiao Dong; dxqhyy@163.com and Quan Du; duquan76@zuaa.zju.edu.cn

Received 29 June 2022; Revised 27 July 2022; Accepted 25 August 2022; Published 15 October 2022

Copyright © 2022 Yunsong Peng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Gem nuclear organelle-associated protein 6 (GEMIN6) is a component of the GEMINS protein family involved in the survival of motor neuron (SMN) complex. SMN interfered with snRNP assembly and mRNA processing resulting in tumorigenesis. We performed this study to explore the association between GEMIN6 and lung adenocarcinoma (LUAD).

Methods. We used The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to collect transcriptomic expression data of LUAD patients and analyze the difference in GEMIN6 expression between normal and tumor tissues of LUAD. qRT-PCR analysis was also performed to detect the expression of GEMIN6 in normal and LUAD cells. The expression of GEMIN6 on the LUAD patient survival outcome was estimated by the Kaplan–Meier curves and Cox analyses. In addition, the Metascape online tool and single-sample GSEA were employed to find out the underlying biological mechanisms of GEMIN6. Furthermore, the correlations of GEMIN6 expression with immune cell infiltration in LUAD were analyzed by ssGSEA and Spearman correlation analysis.

Results. Compared with the normal tissues and cells, the expression of GEMIN6 was significantly higher in LUAD tissues and cells; the high expression GEMIN6 was also found in the advanced pathologic stage and advanced N and T stages of LUAD. GEMIN6 high expression was significantly associated with inferior overall survival. The heat map revealed the top 20 coexpressed genes with GEMIN6, including SF3B6, CPSF3, and PSMB3. Functional enrichment analysis demonstrated that enrichment genes are associated with the cell cycle, mRNA processing, and energy metabolism. Additionally, GEMIN6 was negatively related to the immune cell infiltration in LUAD.

Conclusions. This study demonstrated that GEMIN6 was involved in the tumorigenesis and progression of LUAD. GEMIN6 could be an important molecular marker of poor prognosis and a therapeutic target of LUAD.

1. Introduction

Lung cancer, including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma, is the principal cause of cancer-related death and the second most commonly occurring cancer worldwide, accounting for 18.0% of deaths and 11.4% of cancers diagnosed [1]. The prolongation in survival has been steadily increased for LUAD due to improvements in treatment options in recent years, including molecular-targeted therapy and immunotherapy. Despite these developments, however, the 5-year survival rate is merely 21%, which is remarkably lower than other common cancers [2]. Therefore, determining new molecular pathways and efficient targets is urgent for patients with LUAD.

MicroRNAs are single-stranded noncoding RNAs that play a critical role in silencing target mRNAs. They can abnormally express in human cancers and be involved in carcinogenesis and cancer progression [3, 4]. Gem nuclear organelle-associated protein 6 (GEMIN6), a component of the GEMINS protein family, can oligomerize and form the survival of motor neuron (SMN) complex. SMN interfere
small nuclear ribonucleoprotein (snRNPs) assembly [5–7]. Several prior studies found the association between GEMIN4 and cancer progression, including bladder cancer [8], renal cancer [9], lung cancer [10], and prostate cancer [11] that yield a preliminary insight that the GEMINS protein family was related to the development of malignant tumors. By contrast, studies focused on GEMIN6 are rare, especially on cancer research. In nonsmall cell lung cancer, GEMIN6 was found to accelerate AURKB maturation and c-Myc stabilization to promote the cancer progression [12], while the clear role of GEMIN6 in LUAD remains to be addressed.

Given that, we supposed that GEMIN6 might be involved in LUAD development and could be a potential therapeutic target for LUAD. Herein, we performed this study to explore the role and functions of GEMIN6 in LUAD. The expression levels and impact of GEMIN6 in LUAD were estimated by analyzing data from The Cancer Genome Atlas (TCGA) database. An independent dataset, LUAD were estimated by analyzing data from The Cancer Genome Atlas (TCGA) database. An independent dataset, containing 5% CO2; BEAS-2B cells were cultured in DMEM and NCI-H23 LUAD cell lines and the normal human bronchial epithelial cell line BEAS-2B were purchased from the iCell Bioscience Inc. (China). A549, H1299, SK-MES-1, PC-9, and NCI-H23 were cultured in RPMI-1640 (iCell Bioscience Inc., Shanghai, China) supplemented with 10% FBS at 37°C containing 5% CO2; BEAS-2B cells were cultured in DMEM (iCell Bioscience Inc., Shanghai, China) and 10% FBS at 37°C containing 5% CO2.

2. Materials and Methods

2.1. Data Sources from TCGA and GEO. Firstly, the GEMIN6 expression in pan-cancer was analyzed by the TIMER web-interactive tool [13]. We downloaded the RNA-seq data (FPKM level) and clinicopathological data of LUAD patients from the TCGA database. The patient samples without survival information were excluded. A total of 535 samples were screened for the next step of research. Moreover, in order to eliminate the technical error of the RNA sequencing data, we standardized the data by R software (V3.6.2). FPKM level data was transformed into the TPM (transcripts per million reads) level for the following analysis. The GSE31210 database was downloaded from NCBI as a verification dataset. The detailed clinicopathological features of all samples were shown in Table 1.

2.2. Coexpressed Gene and Functional Enrichment Analysis. R software was used to screen the genes coexpressed with GEMIN6. Spearman correlation analysis was used to examine the correlation between GEMIN6 and coexpressed genes. The top 20 coexpressed genes were shown by the heat map. Metascape (https://metascape.org), an excellent online analysis tool, has the function of functional enrichment and related pathway analyses [14], which was employed for functional enrichment of GEMIN6 coexpressed genes. Statistical significance was identified as p value < 0.05, with a minimum gene count = 3 and an enrichment factor > 1.0. Moreover, to further explore the GEMIN6-related signaling pathway, GSEA analysis was carried out using the clusterProfiler package [15]. The following conditions are considered to be statistically significant: |NES| > 3 and p value < 0.001.

2.3. Prognostic Model. Based on the significant clinical variables from multivariate Cox regression analysis, we further constructed a nomogram as a model for predicting the prognosis of patients with LUAD using R package rms. In accordance with the formula multivariate Cox regression model, the risk score (RS) of each sample was evaluated. Afterward, the samples were categorized as low-risk groups and high-risk groups according to the median value of RS.

2.4. Analysis of Immune Infiltration and GEMIN6 Expression by ssGSEA. To explore the effect of GEMIN6 expression on the immune microenvironment, ssGSEA was performed by the GSEA Package in R [16]. We calculated 24 types of immune cell infiltration according to the expression of immune-related genes from the published gene signature list [17]. Furthermore, the Spearman correlation was carried out to evaluate the relationship of the different immune cell infiltration and GEMIN6 expression.

2.5. Cell Culture. The A549, H1299, SK-MES-1, PC-9, and NCI-H23 LUAD cell lines and the normal human bronchial epithelial cell line BEAS-2B were purchased from the iCell Bioscience Inc. (China). A549, H1299, SK-MES-1, PC-9, and NCI-H23 were cultured in RPMI-1640 (iCell Bioscience Inc., Shanghai, China) supplemented with 10% FBS at 37°C containing 5% CO2; BEAS-2B cells were cultured in DMEM (iCell Bioscience Inc., Shanghai, China) and 10% FBS at 37°C containing 5% CO2.

2.6. qRT-PCR Analysis. Total RNAs were extracted from cells with MolPure® TReasy Plus Total RNA Kit (Yeasen Biotechnology (Shanghai) Co. Ltd., China) and were reversed transcribed into cDNA using the Reverse Transcription Kit (CoWin Bioscience, China). For RT-PCR, the cDNA was amplified using SYBR Premix Ex Taq (Yeasen Biotechnology (Shanghai) Co. Ltd., China) and run on LightCycler® 96 (Roche, Germany). Relative mRNA expression was counted using the 2−ΔΔCT method. The primer sequences of GEMIN6 and β-actin were listed: GEMIN6 forward: 5′-ATTTCACAAGAGGTCCGAGTGAC-3′, reverse 5′-CATGTACGTTGCTATCCAGGC-3′; β-actin forward: 5′-CATGTCAGTTGCTATCCAGGC-3′, reverse 5′-CTCC TTAATGTACGCAGAT-3′.

2.7. Statistical Analysis. The Wilcoxon rank-sum test was applied to estimate the discrepancy between GEMIN6 expression levels in LUAD tissue and normal tissue. The association between clinical factors and the expression level of GEMIN6 was evaluated with the Wilcoxon single-rank test and Kruskal-Wallis test. With the log-rank test, Kaplan-Meier curves were utilized to evaluate the statistical differences in OS between these two different expression groups. Moreover, multivariate analyses based on the Cox regression model were applied to assess the prognosis.
Differences in measurement data among more than two groups were analyzed using ANOVA with the post-Tukey test. Only $p$ values < 0.05 were considered statistically significant.

### 3. Results

#### 3.1. Study Characteristics
A total of 535 unique LUAD individuals were collected based on TCGA database. The following parameters, incorporating demographic and clinicopathological ones were retrieved, including age, gender, race, smoking habit, TNM stages, pathological stages, and GEMIN6 expression. The detailed characteristics of eligible cases was presented in Table 1.

#### 3.2. Expression Status of GEMIN6 in LUAD Tissues
Compared with the normal tissue, GEMIN6 was expressed remarkably higher in a variety of tumor tissues, including LUAD (Figure 1(a)). Compared with the normal tissue, GEMIN6 was expressed remarkably higher in LUAD tissues based on the Wilcoxon rank-sum test ($p < 0.001$) (Figures 1(b) and 1(c)). Notably, compared to the low-GEMIN6 expression group, the high-expression group presented with a higher percentage of the advanced pathologic stage ($p < 0.001$), advanced N stage ($p < 0.001$), and advanced T stage ($p < 0.05$) (Figures 1(d)–1(f)). We also performed cell-level experiment, to detect the expression of GEMIN6 in normal and LUAD cells; the result showed that GEMIN6 was highly expressed in LUAD cell lines (A549, H1299, SK-MES-1, PC-9, and NCI-H23) compared to the normal human bronchial epithelial cells (BEAS-2B) (Figure 1(g)). Additionally, ROC analysis of GEMIN6 in LUAD showed that the AUC value was 0.861 (CI: 0.825–0.898, $p < 0.01$) (Figure 1(h)).

#### 3.3. The Impact of GEMIN6 on the Survival of LUAD Patients
The effect of GEMIN6 on the prognosis of LUAD patients was also assessed. According to Kaplan–Meier

---

**Table 1: Clinical characteristics of the enrolled LUAD cases from the TCGA database.**

| Characteristic         | Levels | Overall |
|------------------------|--------|---------|
| n                      |        | 535     |
| T stage, n (%)         |        |         |
| T1                     | 175    | (32.9%) |
| T2                     | 289    | (54.3%) |
| T3                     | 49     | (9.2%)  |
| T4                     | 19     | (3.6%)  |
| N stage, n (%)         |        |         |
| N0                     | 348    | (67.1%) |
| N1                     | 95     | (18.3%) |
| N2                     | 74     | (14.3%) |
| N3                     | 2      | (0.4%)  |
| M stage, n (%)         |        |         |
| M0                     | 361    | (93.5%) |
| M1                     | 25     | (6.5%)  |
| Pathologic stage, n (%)|        |         |
| Stage I                | 294    | (55.8%) |
| Stage II               | 123    | (23.3%) |
| Stage III              | 84     | (15.9%) |
| Stage IV               | 26     | (4.9%)  |
| Gender, n (%)          |        |         |
| Female                 | 286    | (53.5%) |
| Male                   | 249    | (46.5%) |
| Race, n (%)            |        |         |
| Asian                  | 7      | (1.5%)  |
| Black or African American | 55    | (11.8%) |
| White                  | 460    | (86.8%) |
| Age, n (%)             |        |         |
| ≤65                    | 255    | (49.4%) |
| >65                    | 261    | (50.6%) |
| Smoker, n (%)          |        |         |
| No                     | 75     | (14.4%) |
| Yes                    | 446    | (85.6%) |
| Number pack years smoked, n (%) | | |
| <40                    | 188    | (50.9%) |
| ≥40                    | 181    | (49.1%) |
| GEMIN6 expression      |        |         |
| Low                    | 267    | (49.9%) |
| High                   | 268    | (50.1%) |

---
analysis, LUAD patients with GEMIN6 high expression were remarkably associated with a poor overall survival (OS) than those with GEMIN6 low expression (log-rank tests, \(p = 0.005\)) (Figure 2(a)). Also, the same tendency was observed in the disease-specific survival (DSS) of these two groups (\(p = 0.015\)) (Figure 2(b)). The GSE31210 dataset, originating from the GEO database, was employed to further verify the relationship between OS and GEMIN6 expression levels. Similarly, LUAD patients with GEMIN6 high expression were markedly related to an inferior OS to those with GEMIN6 low expression (\(p < 0.001\)) (Figure 2(c)). A nomogram integrating GEMIN6 and other factors that affect the prognosis of LUAD from TCGA data was presented in Figure 2(d).

In addition, the univariate and multivariate analyses of overall survival according to GEMIN6 expression and other prognostic factors were also performed; the comprehensive information was listed in Table 2. Compared to the GEMIN6 low-expression group, the univariate Cox analysis indicated that the GEMIN6 high-expression group had a poorer OS (hazard ratio (HR): 1.529, 95% CI: 1.136–2.058, \(p = 0.005\)). In addition, the following factors were related to a worse OS in LUAD patients: advanced T stage (HR:
2.317, 95% CI: 1.591-3.375, \( p < 0.001 \)), advanced N stage (HR: 2.601, 95% CI: 1.944-3.480, \( p < 0.001 \)), advanced pathologic stage (HR: 2.664, 95% CI: 1.960-3.621, \( p < 0.001 \)), and unfavorable response group (HR: 2.690, 95% CI: 1.918-3.771, \( p < 0.001 \)). However, there was no obvious difference in the gender, race, age, smoker, or pack-year sets.

Compared to the GEMIN6 low expression group, the multivariate Cox analysis implied that the GEMIN6 high expression group had a poorer OS following adjusting of the pathologic stage, primary therapy outcome, T stage, and N stage (HR: 1.491, 95% CI: 1.063-2.092, \( p = 0.021 \)). The detailed results were presented in Table 2. Additionally, primary therapy outcome, T stage, and N stage were risk factors for the OS of LUAD patients.

A nomogram, integrating GEMIN6 expression, pathologic stage, primary therapy outcome, T stage, and N stage, was built (Figure 2(d)) according to multivariate Cox analysis and the needs of clinical practice. Total points could be obtained from this nomogram, and the higher total point on the nomogram indicated an inferior prognosis.

Figure 2: The prognostic value of GEMIN6 expression in LUAD. (a) Kaplan-Meier curves of OS based on the high or low GEMIN6 expression in the TCGA cohort; (b) Kaplan-Meier curves of DSS based on the high or low GEMIN6 expression in the TCGA cohort; (c) Kaplan-Meier curves of OS based on the high or low GEMIN6 expression in the GSE31210 cohort; (d) a nomogram that integrates GEMIN6 and other prognostic factors in LUAD from TCGA data.

2.317, 95% CI: 1.591-3.375, \( p < 0.001 \)), advanced N stage (HR: 2.601, 95% CI: 1.944-3.480, \( p < 0.001 \)), advanced pathologic stage (HR: 2.664, 95% CI: 1.960-3.621, \( p < 0.001 \)), and unfavorable response group (HR: 2.690, 95% CI: 1.918-3.771, \( p < 0.001 \)). However, there was no obvious difference in the gender, race, age, smoker, or pack-year sets.

Compared to the GEMIN6 low expression group, the multivariate Cox analysis implied that the GEMIN6 high expression group had a poorer OS following adjusting of the pathologic stage, primary therapy outcome, T stage, and N stage (HR: 1.491, 95% CI: 1.063-2.092, \( p = 0.021 \)). The detailed results were presented in Table 2. Additionally, primary therapy outcome, T stage, and N stage were risk factors for the OS of LUAD patients.

A nomogram, integrating GEMIN6 expression, pathologic stage, primary therapy outcome, T stage, and N stage, was built (Figure 2(d)) according to multivariate Cox analysis and the needs of clinical practice. Total points could be obtained from this nomogram, and the higher total point on the nomogram indicated an inferior prognosis.
3.4. GEMIN6-Related Functional Enrichment Analysis. Based on the significant role of GEMIN6 in LUAD, the genes coexpressed with GEMIN6 were also identified. The heat map revealed the top 20 coexpressed genes with GEMIN6, including SF3B6, CPSF3, and PSMB3 (Figure 3(a)). The GO enrichment analysis of genes demonstrated several GEMIN6-related terms in three kinds of functional groups (Figure 3(b)). In the group of cellular components, GEMIN6 was largely involved in the mitochondrial protein complex, ribonucleoprotein complex biogenesis, cell cycle, mRNA processing, and DNA repair. The KEGG pathway revealed that GEMIN6 was largely involved in the ribosome, oxidative phosphorylation, spliceosome, DNA replication, and cell cycle (Figure 3(c)). Furthermore, GSEA analysis was utilized to explore the potential signaling pathways between the low- and high-GEMIN6 expression groups, based on the dataset from MSigDB Collection (h.all.v7.2.symbols.gmt). Our results revealed that the G2M checkpoint, MYC target, and E2F target signaling pathways were highly enriched in patients with overexpression of GEMIN6 (Figures 3(d)–3(f)).

3.5. The Correlations between GEMIN6 Expression and Immune Cell Infiltration. According to the lollipop chart, type 2 T helper cells (Th2) were positively correlated with the level of GEMIN6 expression. Nevertheless, it is worth noting that the expression level of GEMIN6 was negatively associated with T cells, effector memory T cell (Tem), T helper cells, B cells, CD8+ T cell, dendritic cell, and central memory T cell. The detailed results were presented in Figures 4(a)–4(h).

4. Discussion

Despite that promising progress has been made for LUAD therapy over the last decades, the 5-year OS remains merely 21% which was significantly lower than other common cancers [2]. Currently, chemotherapy and targeted therapy are the major treatment strategies for advanced LUAD. However, drug resistance remains the main obstacle for enhancing the clinical outcome of patients with LUAD [18]. Hence, exploring novel molecular mechanisms and efficient therapeutic targets is crucial to improving the OS of patients with LUAD.

This study showed that the expression of GEMIN6 was significantly higher in tumor tissues than normal tissues, particularly in LUAD, which implied that GEMIN6 might be involved in lung carcinogenesis. GEMIN6 high expression was related to an inferior outcome compared with GEMIN6 low expression, indicating that GEMIN6 could be considered as a promising prognostic biomarker in LUAD. Several studies documented that GEMIN4 facilitated cancer cell proliferation in renal cell carcinoma and lung cancer [10, 19]. Verma et al. [19] proposed that genetic alteration of the spliceosomal snRNP, which was consistent with the previous reports. Growing evidence suggests that the GEMINS protein family works as an oncogene and is associated with cancer progression [11, 12, 20]. This study demonstrated that GEMIN6 was remarkably expressed in the advanced T stage, the advanced N stage, and the advanced pathologic stage LUAD, suggesting that GEMIN6 was potentially related to high malignant biological behavior of LUAD. The results of our study provided a basis for clinicians to evaluate and identify high-risk LUAD populations with highly malignant biological behavior.

The heat map in this study also revealed the top 20 GEMIN6-coexpressed genes, including SF3B6, CPSF3, and PSMB3. Tumorigenesis triggered by GEMIN6 might be attributed to suppressing p53 activity via SF3B6 [21], silencing spliceosomal Sm gene expression through PSMB3 [22], and DNA hypermethylation by CPSF3 [23]. Based on these evidence, GEMIN6 was considered as an oncogene and therapeutic target of LUAD. GEMIN6 was a subunit of the SMN complex, which played an important role in the assembly of the spliceosomal snRNPs [5]. However, few reports have revealed the role of GEMIN6 in tumors. The results of functional enrichment analysis indicated that GEMIN6 was highly correlated with the biogenesis and assembly of snRNP, which was consistent with the previous reports. Meanwhile, we also found that GEMIN6 was involved in cell proliferation, including the cell cycle and DNA replication. Considering the worse prognosis of patients with
overexpression of GEMIN6, we speculated that the high GEMIN6 expression could promote the progression of cancer via participating in cell cycle and replication in LUAD.

With the advent of immunotherapy, the tumor microenvironment is a hot topic in the current research. Previous studies have revealed that NSCLC patients with high T lymphocyte infiltration such as CD8+ T cells and CD4+ T cells were related to better OS and effective immunotherapy, compared with patients with low immune cell infiltration [24–26]. Some published studies also reveal the clues of GEMIN genes and immune cells. In the absence of regulatory T cells in scurfy mice, the myopathy-specific autoantibody profile revealed significantly increased the levels of anti-SMN as well as anti-Gemin3 antibodies in scurfy sera [27]. Gao et al. identified GEMIN3 (rs197412) which was independently associated with overall survival in non-Hodgkin’s lymphoma patients, and the prognostic value of GEMIN3 in patient outcomes was also observed in the diffuse large B-cell lymphoma and T-cell lymphoma non-Hodgkin’s lymphoma subtypes [28]. Importantly, our
Figure 4: Continued.
results indicated that GEMIN6 expression levels were negatively associated with immune cell infiltration, including T helper cells, CD8+ T cells, B cells, dendritic cells, and memory T cells. Although the R values were not so high, the p values were all obviously less than 0.05. We have to admit that the results of correlation analysis were not so satisfactory, but these results do indicate that the GEMIN6 expression level might impact the ecology of the immune microenvironment, resulting in a worse prognosis of patients with LUAD. Further analysis is needed in our following study to clear the correlations between GEMIN6 expression and immune cell infiltration in LUAD.

Despite that our findings yield insights into the association between GEMIN6 and LUAD, there were several limitations in this study. Firstly, the data were originated from public databases with unknown quality control. Further studies should be performed to validate the results. Additionally, given the absence of detailed data, we cannot evaluate the role of clinical factors related to LUAD comprehensively. Besides, cellular and clinical experiments should be carried out to elucidate the association between GEMIN6 expression at the mRNA and protein levels. Finally, we offered the underlying mechanisms for GEMIN6 in LUAD; the future research direction should focus on revealing direct mechanisms.

### 5. Conclusions

In conclusion, this study provided a comprehensive insight that GEMIN6 was involved in the tumorigenesis and progression of LUAD. Our findings implied that GEMIN6 could be an important molecular marker of poor prognosis and an underlying therapeutic target of LUAD. Additionally, GEMIN6 could be a predictive biomarker of LUAD patients with immunotherapy.

### Data Availability

All data are available from the corresponding authors under reasonable conditions.

### Conflicts of Interest

There is no conflict of interest between all authors of this article.

### Acknowledgments

This study was supported by the Science and Technology Development Project of Hangzhou (2020ZDS0900) and Zhejiang Traditional Chinese Medicine Science and Technology Program Project (2015ZA194).

### References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.

[2] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA: A Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.

[3] D. Cortinovis, V. Monica, F. Pietrantonio, G. L. Ceresoli, C. M. Spina, and L. Wannesson, “MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises,” Current Pharmaceutical Design, vol. 20, no. 24, pp. 3982–3990, 2014.

[4] Z. Hu, J. Chen, T. Tian et al., “Genetic variants of miRNA sequences and non-small cell lung cancer survival,” The Journal of Clinical Investigation, vol. 118, no. 7, pp. 2600–2608, 2008.

[5] W. Feng, A. K. Gubitz, L. Wan et al., “Gemins modulate the expression and activity of the SMN complex,” Human Molecular Genetics, vol. 14, no. 12, pp. 1605–1611, 2005.

[6] D. Bühler, V. Raker, R. Lührmann, and U. Fischer, “Essential role for the tudor domain of SMN in spliceosomal U snRNP assembly: implications for spinal muscular atrophy,” Human Molecular Genetics, vol. 8, no. 13, pp. 2351–2357, 1999.

[7] L. Pellizzoni, B. Charroux, J. Rappaport, M. Mann, and G. Dreyfuss, “A functional interaction between the survival motor neuron complex and RNA polymerase II,” The Journal of Cell Biology, vol. 152, no. 1, pp. 75–86, 2001.
[8] H. Yang, C. P. Dinney, Y. Ye, Y. Zhu, H. B. Grossman, and X. Wu, “Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer,” *Cancer Research*, vol. 68, no. 7, pp. 2530–2537, 2008.

[9] Y. Horikawa, C. G. Wood, H. Yang et al., “Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma,” *Clinical Cancer Research*, vol. 14, no. 23, pp. 7956–7962, 2008.

[10] X. Fang, Z. Yin, X. Li, L. Xia, and B. Zhou, “Polymorphisms in GEMIN4 and AGO1 genes are associated with the risk of lung cancer: a case-control study in Chinese female non-smokers,” *International Journal of Environmental Research and Public Health*, vol. 13, no. 10, p. 939, 2016.

[11] J. Liu, J. Liu, M. Wei et al., “Genetic variants in the microRNA machinery gene GEMIN4 are associated with risk of prostate cancer: a case-control study of the Chinese Han population,” *DNA and Cell Biology*, vol. 31, no. 7, pp. 1296–1302, 2012.

[12] J. Lin, B. Liu, Y. Zhang et al., “Gemin6 promotes c-Myc stabilization and non-small cell lung cancer progression via accelerating AURKB mRNA maturation,” *Clinical and Translational Medicine*, vol. 12, no. 4, article e811, 2022.

[13] T. Li, J. Fan, B. Wang et al., “TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells,” *Cancer Research*, vol. 77, no. 21, pp. e108–e110, 2017.

[14] Y. Zhou, B. Zhou, L. Pache et al., “Metascape provides a biologist-oriented resource for the analysis of systems-level datasets,” *Nature Communications*, vol. 10, no. 1, p. 1523, 2019.

[15] G. Yu, L. G. Wang, Y. Han, and Q. Y. He, “clusterProfiler: an R package for comparing biological themes among gene clusters,” *OMICS*, vol. 16, no. 5, pp. 284–287, 2012.

[16] S. Hanelmann, R. Castelo, and J. Guinney, “GSVA: gene set variation analysis for microarray and RNA-seq data,” *BMC Bioinformatics*, vol. 14, no. 1, 2013.

[17] G. Bindea, B. Mlecnik, M. Tosolini et al., “Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer,” *Immunity*, vol. 39, no. 4, pp. 782–795, 2013.

[18] J. Rotow and T. G. Bivona, “Understanding and targeting resistance mechanisms in NSCLC,” *Nature Reviews. Cancer*, vol. 17, no. 11, pp. 637–658, 2017.

[19] A. Verma, V. Singh, P. K. Jaiswal, and R. D. Mittal, “Anomalies in miRNAs machinery gene, GEMIN-4 variants suggest renal cell carcinoma risk: a small experimental study from North India,” *Indian Journal of Clinical Biochemistry*, vol. 34, no. 1, pp. 45–51, 2019.

[20] W. Zhu, J. Zhao, J. He et al., “Genetic variants in the microRNA biosynthetic pathway Gemin3 and Gemin4 are associated with a risk of cancer: a meta-analysis,” *PeerJ*, vol. 4, article e1724, 2016.

[21] E. Siebring-van Olst, M. Blijlevens, R. X. de Menezes, I. H. van der Meulen-Muileman, E. F. Smit, and V. W. van Beusechem, “A genome-wide siRNA screening for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment,” *Molecular Oncology*, vol. 11, no. 5, pp. 534–551, 2017.

[22] M. Blijlevens, M. A. Komor, R. Sciarrillo, E. F. Smit, R. J. A. Fijnenman, and V. W. van Beusechem, “Silencing core spliceosome Sm gene expression induces a cytotoxic splicing switch in the proteasome subunit beta 3 mRNA in non-small cell lung cancer cells,” *International Journal of Molecular Sciences*, vol. 21, no. 12, p. 4192, 2020.

[23] Y. Ning, W. Liu, X. Guan, X. Xie, and Y. Zhang, “CPSF3 is a promising prognostic biomarker and predicts recurrence of non-small cell lung cancer,” *Oncology Letters*, vol. 18, no. 3, pp. 2835–2844, 2019.

[24] Y. Geng, Y. Shao, W. He et al., “Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis,” *Cellular Physiology and Biochemistry*, vol. 37, no. 4, pp. 1560–1571, 2015.

[25] F. Petitprez, Y. A. Vano, E. Becht et al., “Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies,” *Cancer Immunology, Immunotherapy*, vol. 67, no. 6, pp. 981–988, 2018.

[26] J. M. Taube, J. Galon, L. M. Sholl et al., “Implications of the tumor immune microenvironment for staging and therapeutics,” *Modern Pathology*, vol. 31, no. 2, pp. 214–234, 2018.

[27] O. K. Yilmaz, S. Haeberle, M. Zhang, M. J. Fritzler, A. H. Enk, and E. N. Hadaschik, “Scurfy mice develop features of connective tissue disease overlap syndrome and mixed connective tissue disease in the absence of regulatory T cells,” *Frontiers in Immunology*, vol. 10, p. 881, 2019.

[28] Y. Gao, L. Diao, H. Li, and Z. Guo, “Single nucleotide polymorphisms of microRNA processing genes and outcome of non-Hodgkin’s lymphoma,” *Oncotargets and Therapy*, vol. 8, pp. 1735–1741, 2015.